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To the Editors: 
 
We present a 43-year-old HIV-positive man (74kg, 178cm) who was admitted with respiratory failure, 
persistent pulmonary infiltrates, fever, pleural effusion, ascites, thrombocytopenia, diffuse 
lymphadenopathy, splenomegaly, Kaposi sarcoma and high serum HHV-8 DNA-levels. The 
antiretroviral treatment-experienced patient had 166 CD4 cells/µl and an HIV-1 viral load of 1.7 Mio 
copies/ml. Lymph node biopsy confirmed the diagnosis of multicentric Castleman disease. 
Antiretroviral therapy was commenced with lamivudine, zidovudine, ritonavir boosted darunavir and 
raltegravir. Intravenous etoposide and valganciclovir were added in accordance with Oksenhendler [1]. 
Because of subsequent multiorgan failure a period of mechanical ventilation and continuous renal 
replacement therapy (CRRT) was required. Continuous venovenous haemodiafiltration (CVVHDF) 
was instituted with a Fresenius Multifiltrate dialysis machine (Fresenius Medical Care, Bad Homburg, 
Germany) using a high-flux polysulfone capillary haemofilter with a membrane surface area of 1.8m
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(Ultraflux
®
 AV 1000S). Blood flow rate was 180mL/min, dialysate flow rate was 1500mL/h, pre-dilution 
substitution flow rate was 1500mL/h and fluid removal rate was 100-200mL/h. Urine production was 
5mL/hour, serum creatinine 47µmol/L, serum albumin 19g/L (normal 40–49g/L) and liver enzymes 
within normal range. Antiretroviral therapy, citalopram, levothyroxine, esomeprazole, ursodeoxycholic 
acid and folic acid were administered via the gastric port and simultaneous enteral nutrition 
(Optifibre®) via the duodenal port of a double-lumen nasogastroduodenal tube. Zidovudine (300mg 
q12h), lamivudine (50mg q24h) and ritonavir (100mg q12h) dosing was in accordance with guidelines 
for patients undergoing CRRT [2]. No such guidelines exist for darunavir and raltegravir. As no dose-
adjustments are necessary for darunavir and raltegravir in renal failure, the usual doses of 600mg and 
400mg q12h, respectively, were continued after the institution of CVVHDF.  
Nevertheless intermittent haemodialysis was found to decrease post-dialysis darunavir concentrations 
by 57% and raltegravir concentrations by 82% from their pre-dialysis levels in a case described by 
Giguère et al [3] suggesting an increased clearance during renal replacement therapy. Similar to 
Giguère et al, Bernard et al also found significant reductions in raltegravir plasma concentrations after 
haemodialysis sessions [4], however, others report no reduction [5]. Due to lack of information 
regarding darunavir and raltegravir dosing in CRRT, the controversial data regarding the effect of 
haemodialysis on raltegravir concentrations [3-5], the presence of hypoalbuminaemia predisposing to 
increased drug clearance and the importance of maintaining antiretroviral drugs within therapeutic 
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range, we determined the clearance of these substances on CVVHDF by pharmacokinetic sampling. 
We were additionally interested to determine whether drug administration via the gastric port with 
simultaneous feeding via the duodenal port of the nasogastroduodenal tube affected drug absorption 
and exposure.  
 
Darunavir and raltegravir pharmacokinetic sampling was performed on day 2 of CVVHDF, 5 days after 
drug commencement. Peripheral plasma samples were taken pre-dose and 2 and 6 hours post-dose 
in order to estimate the area under the time-concentration curve (AUC0-12h) which was calculated 
according to the trapezoidal rule. A rough estimate of total oral clearance (Cl) was determined 
according to the formula Cl = F·Dose/AUC0-12h, (F = oral bioavailability). In order to determine the 
sieving coefficient and CVVHDF drug clearance, additional measurement of darunavir and raltegravir 
concentrations in the filter afferent line, the efferent line and the ultrafiltrate line two hours after drug 
administration were performed. Concentrations were determined by high-pressure liquid 
chromatography and a diode array detector. Results and data from previously published 
pharmacokinetic studies in young, healthy males are shown in the Table.    
Both darunavir and raltegravir were removed by CVVHDF with approximately the same clearance as 
provided by a normally functioning kidney. Absorption of both drugs after suspension and application 
via the gastric port with continued administration of feed via the duodenal port of the double-lumen 
tube was good. After administration of a single dose darunavir/ritonavir 400/100mg in 4 fasted healthy 
volunteers mean time to peak serum concentration (tmax) was 0.75 hours and the mean peak 
concentration (Cmax) was 5.125 ± 0.906mg/ml [6]. The 2-hour post-dose darunavir concentration in our 
patient was higher, reflecting the higher dose administered (600mg). Following ten days of multiple-
dose raltegravir administration (400mg q12h) in fasted volunteers, tmax was 1 hour and Cmax was 
4.96mg/l [7]. In our patient the raltegravir plasma concentration was 2.37mg/L two hours post-dose, 
which can be explained by sampling at a later time-point. For comparison, the reported HIV-1 IC5o for 
darunavir is 0.003 – 0.029 µM (0.0016 – 0.016 mg/L) [8] and the reported IC5o for raltegravir is 
10nmol/L (0.0055mg/L) [9]. Good antiviral coverage was thereby provided throughout. 
We conclude that dose-adjustments are not required for patients receiving darunavir and/or raltegravir 
whilst undergoing CVVHDF and that absorption of darunavir and raltegravir is not significantly affected 
by postpyloric enteral feeding.  
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Table:  Pharmacokinetic parameters of darunavir and raltegravir  
 Darunavir Raltegravir 
Whilst undergoing continuous veno-venous haemodiafiltration: 
Dose (mg) /12h 600 400 
(Quf  + QD) (ml/min) 51.7  51.7  
Dilution factor (df) 0.878 0.878 
C0 (mg/L) 4.4 0.25 
C2 (mg/L) 6.1 2.37 
C6 (mg/L) 5.7 0.47 
AUC0-12h (mg/mL*min) 7.74 0.66 
Cuf (mg/L) 0.7 1.06 
Cpre (mg/L) 5.9 2.32 
Cpost (mg/L) 6.2 2.06 
SC 0.116 0.484 
ClCVVHDF (mL/min) 5.2 22.0 
Oral Cltot (mL/min) 78 606 
Percentage of total oral clearance 
due to CVVHD  
7% 4% 
Published pharmacokinetic parameters: 
  
Qo (extra renal elimination fraction) 0.923 [12] 0.91 [11] 
Total body clearance (intravenous) 
with ritonavir 
100mL/min [12]   
Total oral clearance  600ml/min [13] 
Renal clearance 7.7ml/min 60.5ml/min [7] 
 
Figures in bold are measured figures.  Other figures are derived using the equations given below and in the text.   
AUC = area under the curve, C0 = plasma drug concentration immediately before dosing, C2 = plasma drug 2 hours after dosing, 
C6 = plasma drug concentration 6 hours after dosing, Cuf = ultrafiltrate drug concentration 2 hours after dosing, Cpre = drug 
concentration in plasma taken from the efferent haemodiafilter port (`pre-filter`), Cpost = drug concentration in plasma taken from 
the afferent haemodiafilter port (`post-filter`), SC = sieving coefficient, ClCVVHDF = clearance due to haemodiafiltration, Cltot = total 
clearance Quf = ultrafiltration flow rate, QD = dialysate flow rate. To calculate sieving coefficient (SC) and ClCVVHDF standard 
formulae were used [14, 15]. ClCVVHDF = SC x (Quf  + QD) x df Sieving coefficient (SC) = 2 X Cuf  / (Cpre + Cpost). Dilution factor (df) = 
QBF/(QBF  + QRF). QBF = blood flow rate, QRF = substitution rate 
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